Who Paid My Doc
Nashat Gabrail
Canton, OH Medical Doctor
NPI 1104854751 CMS profile 1305541
4875 Higbee Ave Nw, Canton, OH 44718
General payments
$634,530
Research payments
$43,837
Ownership & investment interest
$0
Research they led as principal investigator
$16,746,783
Through program year 2025, Nashat Gabrail of Canton, OH is reported in the CMS Open Payments database as having received $634,530 across 863 general payments and $43,837 in research payments paid to them. Separately, studies naming them as principal investigator received $16,746,783 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,450 | 58 | |
| 2025 | Research | $12,836 | 19 | |
| 2024 | General | $37,083 | 59 | |
| 2024 | Research | $1,871 | 5 | |
| 2023 | General | $57,208 | 79 | |
| 2023 | Research | $3,033 | 12 | |
| 2022 | General | $110,585 | 125 | |
| 2022 | Research | $23,600 | 1 | |
| 2021 | General | $128,269 | 162 | |
| 2021 | Research | $2,000 | 3 | |
| 2020 | General | $144,578 | 154 | |
| 2019 | General | $152,357 | 226 | |
| 2019 | Research | $497 | 2 |
Beside peers
- Nashat Gabrail
- Ohio median
- Middle half of Ohio
- National median
In program year 2025, general payments to Nashat Gabrail were reported at $4,450. Among 40,289 Ohio profiles paid that year, the median was $159 and the middle half received between $47 and $569.
Show as a table
| Year | Nashat Gabrail | Ohio median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $152,357 | $166 | $50–$652 | $163 |
| 2020 | $144,578 | $110 | $33–$367 | $114 |
| 2021 | $128,269 | $125 | $35–$432 | $132 |
| 2022 | $110,585 | $141 | $41–$498 | $149 |
| 2023 | $57,208 | $150 | $43–$522 | $160 |
| 2024 | $37,083 | $153 | $45–$543 | $164 |
| 2025 | $4,450 | $159 | $47–$569 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
1,337
Drug cost
$3,502,265
Branded share of claims
53.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ocrevus Ocrelizumab | Brand | 23 | $900,712 | |
| Ibrance Palbociclib | Brand | 55 | $859,099 | |
| Inrebic Fedratinib Dihydrochloride | Brand | 13 | $344,460 | |
| Revlimid Lenalidomide | Brand | 18 | $314,431 | |
| Doptelet Avatrombopag Maleate | Brand | 24 | $296,616 | |
| Jakafi Ruxolitinib Phosphate | Brand | 17 | $287,702 | |
| Procrit Epoetin Alfa | Brand | 133 | $132,037 | |
| Zarxio Filgrastim-Sndz | Brand | 121 | $106,202 | |
| Ruxience Rituximab-Pvvr | Brand | 14 | $88,271 | |
| Lupron Depot Leuprolide Acetate | Brand | 36 | $71,585 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 147 billing codesPaid by Medicare
$1,344,313
Medicare patients
147
Services billed
97,060
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 65% | |
| Arthritis | 44% | |
| Chronic kidney disease | 31% | |
| Cancer | 29% | |
| Depression | 29% | |
| Diabetes | 28% | |
| COPD | 28% | |
| Ischemic heart disease | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, ocrelizumab, 1 mg J2350 | Office | 12 | 8,400 | $368,624 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 35 | 5,750 | $603 |
| Injection, methylprednisolone sodium succinate, up to 40 mg J2920 | Office | 22 | 124 | $327 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 61 | 251 | $157 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 19 | 1,720 | $155 |
| Injection, potassium chloride, per 2 meq J3480 | Office | 14 | 390 | $33 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 22 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Doptelet |
|
$30,038 | 24 | — |
| SARCLISA |
|
$1,747 | — | — |
| Vitrakvi |
|
$1,515 | — | — |
| CALQUENCE |
|
$525 | — | — |
| LYNPARZA |
|
$525 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 22 in the dashboard with a free accountRecords
905 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.